関連する実験動画
Updated: Jan 7, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
電子カルテベースのインスリン指示セットを複数病院で実施し、低血糖イベントを削減する
Domenic DiSanti1,2, April Goley2, Avni Garg2
1Department of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska.
AACE endocrinology and diabetes
|December 30, 2025
まとめ
標準化された電子インスリン指示セットの導入は、入院患者の糖尿病患者における低血糖イベントを大幅に減少させました。この質改善イニシアチブは、血糖コントロールを改善し、入院患者の糖尿病管理における標準化されたプロトコルの価値を実証しました。
科学分野:
- 内科学
- 内分泌学
- 質改善
背景:
- 糖尿病患者の入院患者における血糖コントロールは困難であり、低血糖はリスクを増加させる。
- 標準化されたインスリン指示セットは、血糖管理を改善し、有害事象を減らすことができる。
主な方法:
- 10の病院で標準化されたインスリン指示セットを導入する質改善プロジェクトを実施した。
- 指示セットには、インスリンと栄養の不一致、基礎/ボーラス投与、および投与量の正確性に対するフェイルセーフが含まれていた。
- 主要な評価項目は、1000患者日あたりの低血糖日数であり、二次的な評価項目には高血糖とヘモグロビンA1cのオーダーが含まれていた。
結論:
- 必須の標準化された電子インスリン指示セットは、入院患者の低血糖を効果的に減少させた。
- このプロトコルは入院患者の糖尿病管理において価値を示したが、施設ごとのばらつきは、個別化されたアプローチの必要性を示唆している。
関連する概念動画
SBAR II: Application of SBAR
5.6K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.6K
Hypoglycemia and Glucagon
763
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
763
Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
Insulin Formulations: Types and Delivery
597
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
597
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540

